Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$1.8M
Filings
124
Firms Hired
3
Active Period
2008–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Humane Correctional Health Care Act
2026 · second_quarter · Firm: PERSONALIZED MEDICINE COALITION
Congressional Personalized Medicine Caucus Genetic Testing and Genomic Sequencing for Rare Diseases H.R.5269 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 3514 Improving Seniors Timely Access to Care Implementation of the Inflation Reduction Act of 2022 Medicare Drug Price Negotiation Provisions Considerations for the use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause; Draft Guidance [FDA-2026-D-1256-0002] Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2027 Rates; Requirements for Quality Programs; and Other Policy Changes [CMS-1849-P] Interoperability and Prior Authorization Proposed Rule Request for Information Laboratory Services [CMS-0062-P] Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community
Client expense: $50,000 · Firm income: —
Matched citations: H.R. 3514
ERAP Improvement Act of 2021
2026 · second_quarter · Firm: PERSONALIZED MEDICINE COALITION
Congressional Personalized Medicine Caucus Genetic Testing and Genomic Sequencing for Rare Diseases H.R.5269 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 3514 Improving Seniors Timely Access to Care Implementation of the Inflation Reduction Act of 2022 Medicare Drug Price Negotiation Provisions Considerations for the use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause; Draft Guidance [FDA-2026-D-1256-0002] Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2027 Rates; Requirements for Quality Programs; and Other Policy Changes [CMS-1849-P] Interoperability and Prior Authorization Proposed Rule Request for Information Laboratory Services [CMS-0062-P] Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community
Client expense: $50,000 · Firm income: —
Matched citations: H.R.5269
Methane Waste Prevention Act of 2021
2026 · first_quarter · Firm: PERSONALIZED MEDICINE COALITION
Congressional Personalized Medicine Caucus Genetic Testing and Genomic Sequencing for Rare Diseases S. 832/H.R. 1492 the Ensuring Pathways to Innovative Cures Act H.R. 946 Optimizing Research Progress Hope and New Cures Act H.R. 1672 Maintaining Investments in New Innovation Act S.2761/H.R.5269 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act Implementation of the Inflation Reduction Act of 2022 Medicare Drug Price Negotiation Provisions Implementation of Rural Health Transformation Program Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model [CMS-5546-P] Global Benchmark for Efficient Drug Pricing (GLOBE) Model [CMS-5545-P] Reclassification of Nucleic Acid-Based Test Systems for Use with a Corresponding Approved Oncology Therapeutic Product; Proposed Amendment; Proposed Order; Request for Comments [Docket No. FDA-2025-N-4622] Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community
Client expense: $40,000 · Firm income: —
Matched citations: H.R. 1492
Connect America Act of 2021
2026 · first_quarter · Firm: PERSONALIZED MEDICINE COALITION
Congressional Personalized Medicine Caucus Genetic Testing and Genomic Sequencing for Rare Diseases S. 832/H.R. 1492 the Ensuring Pathways to Innovative Cures Act H.R. 946 Optimizing Research Progress Hope and New Cures Act H.R. 1672 Maintaining Investments in New Innovation Act S.2761/H.R.5269 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act Implementation of the Inflation Reduction Act of 2022 Medicare Drug Price Negotiation Provisions Implementation of Rural Health Transformation Program Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model [CMS-5546-P] Global Benchmark for Efficient Drug Pricing (GLOBE) Model [CMS-5545-P] Reclassification of Nucleic Acid-Based Test Systems for Use with a Corresponding Approved Oncology Therapeutic Product; Proposed Amendment; Proposed Order; Request for Comments [Docket No. FDA-2025-N-4622] Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community
Client expense: $40,000 · Firm income: —
Matched citations: H.R. 1672
ERAP Improvement Act of 2021
2026 · first_quarter · Firm: PERSONALIZED MEDICINE COALITION
Congressional Personalized Medicine Caucus Genetic Testing and Genomic Sequencing for Rare Diseases S. 832/H.R. 1492 the Ensuring Pathways to Innovative Cures Act H.R. 946 Optimizing Research Progress Hope and New Cures Act H.R. 1672 Maintaining Investments in New Innovation Act S.2761/H.R.5269 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act Implementation of the Inflation Reduction Act of 2022 Medicare Drug Price Negotiation Provisions Implementation of Rural Health Transformation Program Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model [CMS-5546-P] Global Benchmark for Efficient Drug Pricing (GLOBE) Model [CMS-5545-P] Reclassification of Nucleic Acid-Based Test Systems for Use with a Corresponding Approved Oncology Therapeutic Product; Proposed Amendment; Proposed Order; Request for Comments [Docket No. FDA-2025-N-4622] Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community
Client expense: $40,000 · Firm income: —
Matched citations: H.R.5269
Congressional Personalized Medicine Caucus Genetic Testing and Genomic Sequencing for Rare Diseases S. 832/H.R. 1492 the Ensuring Pathways to Innovative Cures Act H.R. 946 Optimizing Research Progress Hope and New Cures Act H.R. 1672 Maintaining Investments in New Innovation Act S.2761/H.R.5269 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act Implementation of the Inflation Reduction Act of 2022 Medicare Drug Price Negotiation Provisions Implementation of Rural Health Transformation Program Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model [CMS-5546-P] Global Benchmark for Efficient Drug Pricing (GLOBE) Model [CMS-5545-P] Reclassification of Nucleic Acid-Based Test Systems for Use with a Corresponding Approved Oncology Therapeutic Product; Proposed Amendment; Proposed Order; Request for Comments [Docket No. FDA-2025-N-4622] Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community
Client expense: $40,000 · Firm income: —
Matched citations: H.R. 946
Every Veteran Counts Act of 2021
2026 · first_quarter · Firm: PERSONALIZED MEDICINE COALITION
Congressional Personalized Medicine Caucus Genetic Testing and Genomic Sequencing for Rare Diseases S. 832/H.R. 1492 the Ensuring Pathways to Innovative Cures Act H.R. 946 Optimizing Research Progress Hope and New Cures Act H.R. 1672 Maintaining Investments in New Innovation Act S.2761/H.R.5269 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act Implementation of the Inflation Reduction Act of 2022 Medicare Drug Price Negotiation Provisions Implementation of Rural Health Transformation Program Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model [CMS-5546-P] Global Benchmark for Efficient Drug Pricing (GLOBE) Model [CMS-5545-P] Reclassification of Nucleic Acid-Based Test Systems for Use with a Corresponding Approved Oncology Therapeutic Product; Proposed Amendment; Proposed Order; Request for Comments [Docket No. FDA-2025-N-4622] Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community
Client expense: $40,000 · Firm income: —
Matched citations: S.2761
GREEN Building Jobs Act of 2021
2026 · first_quarter · Firm: PERSONALIZED MEDICINE COALITION
Congressional Personalized Medicine Caucus Genetic Testing and Genomic Sequencing for Rare Diseases S. 832/H.R. 1492 the Ensuring Pathways to Innovative Cures Act H.R. 946 Optimizing Research Progress Hope and New Cures Act H.R. 1672 Maintaining Investments in New Innovation Act S.2761/H.R.5269 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act Implementation of the Inflation Reduction Act of 2022 Medicare Drug Price Negotiation Provisions Implementation of Rural Health Transformation Program Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model [CMS-5546-P] Global Benchmark for Efficient Drug Pricing (GLOBE) Model [CMS-5545-P] Reclassification of Nucleic Acid-Based Test Systems for Use with a Corresponding Approved Oncology Therapeutic Product; Proposed Amendment; Proposed Order; Request for Comments [Docket No. FDA-2025-N-4622] Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community
Client expense: $40,000 · Firm income: —
Matched citations: S. 832
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2025 · second_quarter · Firm: PERSONALIZED MEDICINE COALITION
Congressional Personalized Medicine Caucus S. 832/H.R. 1492 the Ensuring Pathways to Innovative Cures Act H.R. 946 Optimizing Research Progress Hope and New Cures Act H.R. 1672 Maintaining Investments in New Innovation Act House Energy and Commerce Committee Privacy Working Group Request for Information CMS Implementation of Medicare Drug Price Negotiation Program/ Medicare Drug Price Negotiation Program; Draft Guidance for the Medicare Drug Price Negotiation Program: Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2028 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026, 2027, and 2028 Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2026 Rates; Requirements for Quality Programs; and Other Policy Changes (CMS-1833-P) Office of Science and Technology Policy Request for Information on the Development of an Artificial Intelligence (AI) Action Plan Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations [FDA-2024-D-4488] Considerations for the Use of Artificial Intelligence to Support Regulatory Decision Making for Drug and Biological Products [FDA-2024-D-4689] Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community
Client expense: $46,000 · Firm income: —
Matched citations: H.R. 1492
Maintaining Investments in New Innovation Act
2025 · second_quarter · Firm: PERSONALIZED MEDICINE COALITION
Congressional Personalized Medicine Caucus S. 832/H.R. 1492 the Ensuring Pathways to Innovative Cures Act H.R. 946 Optimizing Research Progress Hope and New Cures Act H.R. 1672 Maintaining Investments in New Innovation Act House Energy and Commerce Committee Privacy Working Group Request for Information CMS Implementation of Medicare Drug Price Negotiation Program/ Medicare Drug Price Negotiation Program; Draft Guidance for the Medicare Drug Price Negotiation Program: Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2028 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026, 2027, and 2028 Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2026 Rates; Requirements for Quality Programs; and Other Policy Changes (CMS-1833-P) Office of Science and Technology Policy Request for Information on the Development of an Artificial Intelligence (AI) Action Plan Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations [FDA-2024-D-4488] Considerations for the Use of Artificial Intelligence to Support Regulatory Decision Making for Drug and Biological Products [FDA-2024-D-4689] Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community
Client expense: $46,000 · Firm income: —
Matched citations: H.R. 1672
Congressional Personalized Medicine Caucus S. 832/H.R. 1492 the Ensuring Pathways to Innovative Cures Act H.R. 946 Optimizing Research Progress Hope and New Cures Act H.R. 1672 Maintaining Investments in New Innovation Act House Energy and Commerce Committee Privacy Working Group Request for Information CMS Implementation of Medicare Drug Price Negotiation Program/ Medicare Drug Price Negotiation Program; Draft Guidance for the Medicare Drug Price Negotiation Program: Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2028 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026, 2027, and 2028 Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2026 Rates; Requirements for Quality Programs; and Other Policy Changes (CMS-1833-P) Office of Science and Technology Policy Request for Information on the Development of an Artificial Intelligence (AI) Action Plan Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations [FDA-2024-D-4488] Considerations for the Use of Artificial Intelligence to Support Regulatory Decision Making for Drug and Biological Products [FDA-2024-D-4689] Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community
Client expense: $46,000 · Firm income: —
Matched citations: H.R. 946
Congressional Personalized Medicine Caucus S. 832/H.R. 1492 the Ensuring Pathways to Innovative Cures Act H.R. 946 Optimizing Research Progress Hope and New Cures Act H.R. 1672 Maintaining Investments in New Innovation Act House Energy and Commerce Committee Privacy Working Group Request for Information CMS Implementation of Medicare Drug Price Negotiation Program/ Medicare Drug Price Negotiation Program; Draft Guidance for the Medicare Drug Price Negotiation Program: Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2028 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026, 2027, and 2028 Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2026 Rates; Requirements for Quality Programs; and Other Policy Changes (CMS-1833-P) Office of Science and Technology Policy Request for Information on the Development of an Artificial Intelligence (AI) Action Plan Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations [FDA-2024-D-4488] Considerations for the Use of Artificial Intelligence to Support Regulatory Decision Making for Drug and Biological Products [FDA-2024-D-4689] Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community
Client expense: $46,000 · Firm income: —
Matched citations: S. 832
Methane Waste Prevention Act of 2021
2025 · third_quarter · Firm: PERSONALIZED MEDICINE COALITION
Congressional Personalized Medicine Caucus Genetic Testing and Genomic Sequencing for Rare Diseases H.R. 2471 Right Drug Dose Now Act S. 832/H.R. 1492 the Ensuring Pathways to Innovative Cures Act H.R. 946 Optimizing Research Progress Hope and New Cures Act H.R. 1672 Maintaining Investments in New Innovation Act Implementation of the Inflation Reduction Act of 2022 Medicare Drug Price Negotiation Provisions Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program (CMS-1832-P) Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2026 Rates; Requirements for Quality Programs; and Other Policy Changes (CMS-1833-P) Medicare and Medicaid Programs: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; Quality Reporting Programs; Overall Hospital Quality Star Ratings; and Hospital Price Transparency (CMS-1834-P) Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community
Client expense: $47,000 · Firm income: —
Matched citations: H.R. 1492
Connect America Act of 2021
2025 · third_quarter · Firm: PERSONALIZED MEDICINE COALITION
Congressional Personalized Medicine Caucus Genetic Testing and Genomic Sequencing for Rare Diseases H.R. 2471 Right Drug Dose Now Act S. 832/H.R. 1492 the Ensuring Pathways to Innovative Cures Act H.R. 946 Optimizing Research Progress Hope and New Cures Act H.R. 1672 Maintaining Investments in New Innovation Act Implementation of the Inflation Reduction Act of 2022 Medicare Drug Price Negotiation Provisions Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program (CMS-1832-P) Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2026 Rates; Requirements for Quality Programs; and Other Policy Changes (CMS-1833-P) Medicare and Medicaid Programs: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; Quality Reporting Programs; Overall Hospital Quality Star Ratings; and Hospital Price Transparency (CMS-1834-P) Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community
Client expense: $47,000 · Firm income: —
Matched citations: H.R. 1672
Consolidated Appropriations Act, 2022
2025 · third_quarter · Firm: PERSONALIZED MEDICINE COALITION
Congressional Personalized Medicine Caucus Genetic Testing and Genomic Sequencing for Rare Diseases H.R. 2471 Right Drug Dose Now Act S. 832/H.R. 1492 the Ensuring Pathways to Innovative Cures Act H.R. 946 Optimizing Research Progress Hope and New Cures Act H.R. 1672 Maintaining Investments in New Innovation Act Implementation of the Inflation Reduction Act of 2022 Medicare Drug Price Negotiation Provisions Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program (CMS-1832-P) Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2026 Rates; Requirements for Quality Programs; and Other Policy Changes (CMS-1833-P) Medicare and Medicaid Programs: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; Quality Reporting Programs; Overall Hospital Quality Star Ratings; and Hospital Price Transparency (CMS-1834-P) Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community
Client expense: $47,000 · Firm income: —
Matched citations: H.R. 2471
Congressional Personalized Medicine Caucus Genetic Testing and Genomic Sequencing for Rare Diseases H.R. 2471 Right Drug Dose Now Act S. 832/H.R. 1492 the Ensuring Pathways to Innovative Cures Act H.R. 946 Optimizing Research Progress Hope and New Cures Act H.R. 1672 Maintaining Investments in New Innovation Act Implementation of the Inflation Reduction Act of 2022 Medicare Drug Price Negotiation Provisions Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program (CMS-1832-P) Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2026 Rates; Requirements for Quality Programs; and Other Policy Changes (CMS-1833-P) Medicare and Medicaid Programs: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; Quality Reporting Programs; Overall Hospital Quality Star Ratings; and Hospital Price Transparency (CMS-1834-P) Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community
Client expense: $47,000 · Firm income: —
Matched citations: H.R. 946
GREEN Building Jobs Act of 2021
2025 · third_quarter · Firm: PERSONALIZED MEDICINE COALITION
Congressional Personalized Medicine Caucus Genetic Testing and Genomic Sequencing for Rare Diseases H.R. 2471 Right Drug Dose Now Act S. 832/H.R. 1492 the Ensuring Pathways to Innovative Cures Act H.R. 946 Optimizing Research Progress Hope and New Cures Act H.R. 1672 Maintaining Investments in New Innovation Act Implementation of the Inflation Reduction Act of 2022 Medicare Drug Price Negotiation Provisions Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program (CMS-1832-P) Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2026 Rates; Requirements for Quality Programs; and Other Policy Changes (CMS-1833-P) Medicare and Medicaid Programs: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; Quality Reporting Programs; Overall Hospital Quality Star Ratings; and Hospital Price Transparency (CMS-1834-P) Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community
Client expense: $47,000 · Firm income: —
Matched citations: S. 832
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2025 · second_quarter · Firm: PERSONALIZED MEDICINE COALITION
Congressional Personalized Medicine Caucus S. 832/H.R. 1492 the Ensuring Pathways to Innovative Cures Act H.R. 946 Optimizing Research Progress Hope and New Cures Act H.R. 1672 Maintaining Investments in New Innovation Act House Energy and Commerce Committee Privacy Working Group Request for Information CMS Implementation of Medicare Drug Price Negotiation Program/ Medicare Drug Price Negotiation Program; Draft Guidance for the Medicare Drug Price Negotiation Program: Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2028 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026, 2027, and 2028 Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2026 Rates; Requirements for Quality Programs; and Other Policy Changes (CMS-1833-P) Office of Science and Technology Policy Request for Information on the Development of an Artificial Intelligence (AI) Action Plan Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations [FDA-2024-D-4488] Considerations for the Use of Artificial Intelligence to Support Regulatory Decision Making for Drug and Biological Products [FDA-2024-D-4689] Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community
Client expense: $46,000 · Firm income: —
Matched citations: H.R. 1492
Maintaining Investments in New Innovation Act
2025 · second_quarter · Firm: PERSONALIZED MEDICINE COALITION
Congressional Personalized Medicine Caucus S. 832/H.R. 1492 the Ensuring Pathways to Innovative Cures Act H.R. 946 Optimizing Research Progress Hope and New Cures Act H.R. 1672 Maintaining Investments in New Innovation Act House Energy and Commerce Committee Privacy Working Group Request for Information CMS Implementation of Medicare Drug Price Negotiation Program/ Medicare Drug Price Negotiation Program; Draft Guidance for the Medicare Drug Price Negotiation Program: Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2028 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026, 2027, and 2028 Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2026 Rates; Requirements for Quality Programs; and Other Policy Changes (CMS-1833-P) Office of Science and Technology Policy Request for Information on the Development of an Artificial Intelligence (AI) Action Plan Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations [FDA-2024-D-4488] Considerations for the Use of Artificial Intelligence to Support Regulatory Decision Making for Drug and Biological Products [FDA-2024-D-4689] Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community
Client expense: $46,000 · Firm income: —
Matched citations: H.R. 1672
Congressional Personalized Medicine Caucus S. 832/H.R. 1492 the Ensuring Pathways to Innovative Cures Act H.R. 946 Optimizing Research Progress Hope and New Cures Act H.R. 1672 Maintaining Investments in New Innovation Act House Energy and Commerce Committee Privacy Working Group Request for Information CMS Implementation of Medicare Drug Price Negotiation Program/ Medicare Drug Price Negotiation Program; Draft Guidance for the Medicare Drug Price Negotiation Program: Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2028 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026, 2027, and 2028 Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2026 Rates; Requirements for Quality Programs; and Other Policy Changes (CMS-1833-P) Office of Science and Technology Policy Request for Information on the Development of an Artificial Intelligence (AI) Action Plan Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations [FDA-2024-D-4488] Considerations for the Use of Artificial Intelligence to Support Regulatory Decision Making for Drug and Biological Products [FDA-2024-D-4689] Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community
Client expense: $46,000 · Firm income: —
Matched citations: H.R. 946
Congressional Personalized Medicine Caucus S. 832/H.R. 1492 the Ensuring Pathways to Innovative Cures Act H.R. 946 Optimizing Research Progress Hope and New Cures Act H.R. 1672 Maintaining Investments in New Innovation Act House Energy and Commerce Committee Privacy Working Group Request for Information CMS Implementation of Medicare Drug Price Negotiation Program/ Medicare Drug Price Negotiation Program; Draft Guidance for the Medicare Drug Price Negotiation Program: Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2028 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026, 2027, and 2028 Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2026 Rates; Requirements for Quality Programs; and Other Policy Changes (CMS-1833-P) Office of Science and Technology Policy Request for Information on the Development of an Artificial Intelligence (AI) Action Plan Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations [FDA-2024-D-4488] Considerations for the Use of Artificial Intelligence to Support Regulatory Decision Making for Drug and Biological Products [FDA-2024-D-4689] Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community
Client expense: $46,000 · Firm income: —
Matched citations: S. 832
American Relief Act, 2025
2024 · fourth_quarter · Firm: PERSONALIZED MEDICINE COALITION
FY 2025 Food and Drug Administration Budget Priorities for CDER, CBER and CDRH FY 2025 National Institutes of Health Budget Priorities H.R. 10545 The American Relief Act of 2025
Client expense: $41,000 · Firm income: —
Matched citations: H.R. 10545
Access to Genetic Counselor Services Act of 2023
2024 · fourth_quarter · Firm: PERSONALIZED MEDICINE COALITION
Congressional Personalized Medicine Caucus Precision Medicine Answers for Kids Today Act and Medicaid Early Periodic Screening, Diagnostic and Treatment Benefit 21st Century Cures 2.1 Oversight of Laboratory Developed Tests H.R. 3876/S. 2323 Access to Genetic Counselor Services Act H.R. 5539/S. 3131 Optimizing Research Progress Hope And New (ORPHAN) Cures Act H.R. 5547/S.476 Maintaining Investments in New Innovation (MINI) Act H.R. 7174 Ensuring Pathways to Innovative Cures (EPIC) Act CMS Implementation of Medicare Drug Price Negotiation Program/ Medicare Drug Price Negotiation Program Medicare and Medicaid Programs; CY 2025 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; etc (CMS-1807-P) FDA Center for Drug Evaluation and Research AI Council Priorities Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community
Client expense: $41,000 · Firm income: —
Matched citations: H.R. 3876
ORPHAN Cures Act
2024 · fourth_quarter · Firm: PERSONALIZED MEDICINE COALITION
Congressional Personalized Medicine Caucus Precision Medicine Answers for Kids Today Act and Medicaid Early Periodic Screening, Diagnostic and Treatment Benefit 21st Century Cures 2.1 Oversight of Laboratory Developed Tests H.R. 3876/S. 2323 Access to Genetic Counselor Services Act H.R. 5539/S. 3131 Optimizing Research Progress Hope And New (ORPHAN) Cures Act H.R. 5547/S.476 Maintaining Investments in New Innovation (MINI) Act H.R. 7174 Ensuring Pathways to Innovative Cures (EPIC) Act CMS Implementation of Medicare Drug Price Negotiation Program/ Medicare Drug Price Negotiation Program Medicare and Medicaid Programs; CY 2025 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; etc (CMS-1807-P) FDA Center for Drug Evaluation and Research AI Council Priorities Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community
Client expense: $41,000 · Firm income: —
Matched citations: H.R. 5539
Maintaining Investments in New Innovation Act
2024 · fourth_quarter · Firm: PERSONALIZED MEDICINE COALITION
Congressional Personalized Medicine Caucus Precision Medicine Answers for Kids Today Act and Medicaid Early Periodic Screening, Diagnostic and Treatment Benefit 21st Century Cures 2.1 Oversight of Laboratory Developed Tests H.R. 3876/S. 2323 Access to Genetic Counselor Services Act H.R. 5539/S. 3131 Optimizing Research Progress Hope And New (ORPHAN) Cures Act H.R. 5547/S.476 Maintaining Investments in New Innovation (MINI) Act H.R. 7174 Ensuring Pathways to Innovative Cures (EPIC) Act CMS Implementation of Medicare Drug Price Negotiation Program/ Medicare Drug Price Negotiation Program Medicare and Medicaid Programs; CY 2025 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; etc (CMS-1807-P) FDA Center for Drug Evaluation and Research AI Council Priorities Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community
Client expense: $41,000 · Firm income: —
Matched citations: H.R. 5547
Source: Senate LDA